Este sitio web utiliza tecnologías de seguimiento, como cookies, para brindar una mejor experiencia al usuario. Si continúa utilizando este sitio, entonces reconoce nuestro uso de tecnologías de seguimiento. Para obtener información adicional, consulte nuestra Política de Privacidad.
REGÍSTRESE
For those of you watching the 49ers vs. Seahawks game on Thanksgiving night, you might have seen a heartwarming half-time segment that also caught the attention of some folks here at the Cancer Research Institute.
For the past few months, Seattle Seahawks’ quarterback Russell Wilson has spent every Tuesday visiting kids in the cancer ward at Seattle Children’s hospital—bringing them football souvenirs and general positive energy to make their stay in the hospital just a bit less bleak.
Seattle Children’s is home to some of the most exciting research being done on immunotherapy for pediatric cancers like leukemia, under the direction of Dr. Michael Jensen, whose research CRI has supported.
In addition to admiring the overall awesomeness of the work being done at Seattle Children’s, CRI was excited to see that the spot featured the remarkable story of Milton Wright, a 20-year-old former football prodigy who beat advanced leukemia with the help of a new immunotherapy called CAR T cell therapy. Milton’s story was featured in our “30 Days, 30 Stories” campaign, which appeared on our new patient oriented website TheAnswerToCancer.org as part of Cancer Immunotherapy Month in June.
Inmunoterapia vs. Quimioterapia: ¿Cual es la diferencia?
Read Next Article
Comuníquese con nosotros
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Directorio de Personal
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).